SARS-CoV-2 proteins and anti-COVID-19 drugs induce lytic reactivation of an oncogenic virus
Open Access
- 3 June 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Communications Biology
- Vol. 4 (1), 1-6
- https://doi.org/10.1038/s42003-021-02220-z
Abstract
An outbreak of the novel coronavirus SARS-CoV-2, the causative agent of Coronavirus Disease-2019 (COVID-19), a respiratory disease, has infected almost one hundred million people since the end of 2019, killed over two million, and caused worldwide social and economic disruption. Because the mechanisms of SARS-CoV-2 infection of host cells and its pathogenesis remain largely unclear, there are currently no antiviral drugs with proven efficacy. Besides severe respiratory and systematic symptoms, several comorbidities increase risk of fatal disease outcome. Therefore, it is required to investigate the impacts of COVID-19 on pre-existing diseases of patients, such as cancer and other infectious diseases. In the current study, we report that SARS-CoV-2 encoded proteins and some currently used anti-COVID-19 drugs are able to induce lytic reactivation of Kaposi’s sarcoma-associated herpesvirus (KSHV), one of major human oncogenic viruses, through manipulation of intracellular signaling pathways. Our data indicate that those KSHV + patients especially in endemic areas exposure to COVID-19 or undergoing the treatment may have increased risks to develop virus-associated cancers, even after they have fully recovered from COVID-19.Keywords
Funding Information
- U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA228166)
This publication has 32 references indexed in Scilit:
- Reactivation and Lytic Replication of Kaposi’s Sarcoma-Associated Herpesvirus: An UpdateFrontiers in Microbiology, 2017
- Clinical Features and Outcomes of Patients With Symptomatic Kaposi Sarcoma Herpesvirus (KSHV)-associated Inflammation: Prospective Characterization of KSHV Inflammatory Cytokine Syndrome (KICS)Clinical Infectious Diseases, 2015
- CD147 and downstream ADAMTSs promote the tumorigenicity of Kaposi's sarcoma-associated herpesvirus infected endothelial cellsOncotarget, 2015
- High prevalence of early childhood infection by Kaposi's sarcoma-associated herpesvirus in a minority population in ChinaClinical Microbiology & Infection, 2014
- Generation of a doxycycline-inducible KSHV producer cell line of endothelial origin: Maintenance of tight latency with efficient reactivation upon inductionJournal of Virological Methods, 2011
- Extracellular Hsp90 serves as a co-factor for NF-κB activation and cellular pathogenesis induced by an oncogenic herpesvirus.2011
- Kaposi's sarcoma and its associated herpesvirusNature Reviews Cancer, 2010
- Direct Activation of Emmprin and Associated Pathogenesis by an Oncogenic HerpesvirusCancer Research, 2010
- Use of the red fluorescent protein as a marker of Kaposi's sarcoma-associated herpesvirus lytic gene expressionVirology, 2004
- Identification of Herpesvirus-Like DNA Sequences in AIDS-Sssociated Kaposi's SarcomaScience, 1994